The American Journal of Managed Care

TP53-Mutated MDS/AML Posttransplant Treatment Gaps

The rate of relapse among patients with TP53-mutated myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) was similar among those who underwent allogeneic hematopoietic stem cell transplant ...
The American Journal of Managed Care

Neutrophil Subset Changes Give Insight Into First Mechanisms of MDS, AML

Emergency hemopoiesis may maintain blood counts and a proinflammatory environment in MDS, AML, and ICUS. Altered neutrophil subset distributions in MDS and AML show diagnostic sensitivity, with ...
Cure Today

Venclexta Plus Mavenclad Boosts Response Rates in AML, MDS

Mavenclad and Venclexta combination achieved a 96% ORR in newly diagnosed AML and high-risk MDS patients, with high CR rates in MRD-negative individuals. The study reported a 2-year OS rate of 100% ...
Oncology Nurse Advisor

Enasidenib Is a Safe and Effective Intervention in IDH2-Mutated AML and MDS

Researchers sought to determine whether combining enasidenib with venetoclax would be effective in patients with IDH2-mutated ...
Healio

VIDEO: Progression of pre-MDS conditions into MDS AML

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. So, in terms of preventing MDS, that's a ...
Monthly Prescribing Reference

Grafapex Approved as Part of Conditioning Regimen for HSCT in AML, MDS Patients

Findings showed the hazard ratio for OS compared with busulfan was 0.67 in all randomized patients. The Food and Drug Administration (FDA) has approved Grafapex ™ (treosulfan) for injection with ...
Seeking Alpha

Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials

Tuspetinib selected for a prestigious national clinical research program for ability to target broad spectrum of AML and MDS populations Trials to test tuspetinib in targeted drug combinations for ...
MedPage Today

FDA Approves Treosulfan as Part of AML/MDS Conditioning Regimen

The FDA approved treosulfan (Grafapex) with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in patients ages 1 year and older with acute myeloid leukemia ...
ascopubs.org

Implementation of and Systems-Level Barriers to Guideline-Driven Germline Genetic Evaluation in the Care of Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia

Innovative models of germline genetic evaluation are needed for patients with MDS/AML to address systems-level barriers to care, including the development of inpatient genetic counseling and testing ...
ascopubs.org

The Times, They Are A-Changing: The Impact of Next-Generation Sequencing on Diagnosis, Classification, and Prognostication of Myeloid Malignancies With Focus on Myelodysplastic ...

•Genomic characterization determines diagnosis, classification, and prognostication of the myeloid malignancies myelodysplastic syndrome (MDS) and AML. •Recognizing genetic lesions as invariable ...
Nasdaq

Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials

SAN DIEGO and TORONTO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly ...